Moderna begins trials of HIV vaccine which relies on same dubious mRNA technology as some covid jabs
Moderna was last year’s third-best-performing stock in the S&P – now it's this year’s worst. Moderna has launched a trial of a HIV vaccine which uses the same breakthrough mRNA technology harnessed for its covid jab. The US pharmaceutical giant has recruited 56 volunteers who do not have HIV to test its jab. The first participants…
Read More...
Read More...